DANMEDA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 600,630 | 614,802 | 490,615 | 549,705 | 602,073 | 529,308 | 476,550 | 551,102 |
| Profit before tax | 43,651 | 107,046 | 67,967 | 117,362 | 181,900 | 160,583 | 92,742 | 179,541 |
| Net profit | 35,394 | 91,500 | 54,968 | 98,346 | 154,698 | 135,965 | 80,670 | 150,734 |
| Equity | 680,728 | 732,228 | 687,194 | 785,540 | 740,238 | 876,203 | 956,873 | 1,107,607 |
| Liabilities | 106,949 | 75,870 | 63,731 | 24,506 | 72,376 | 28,895 | 27,360 | 25,395 |
| Non-current assets | 296,742 | 274,811 | 249,067 | 222,463 | 215,564 | 217,387 | 217,132 | 219,131 |
| Current assets | 490,935 | 533,287 | 501,858 | 587,583 | 597,050 | 687,711 | 767,101 | 913,871 |
| Total assets | 787,677 | 808,098 | 750,925 | 810,046 | 812,614 | 905,098 | 984,233 | 1,133,002 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 62,274 | 56,560 | 53,655 |
| Social insurance contributions | - | - | - | - | - | 8,170 | 8,351 | 8,664 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -8.7% | +2.4% | -20.2% | +12.0% | +9.5% | -12.1% | -10.0% | +15.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.5% | 11.3% | 7.3% | 12.1% | 19.0% | 15.0% | 8.2% | 13.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 5.2% | 12.5% | 8.0% | 12.5% | 20.9% | 15.5% | 8.4% | 13.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.9% | 14.9% | 11.2% | 17.9% | 25.7% | 25.7% | 16.9% | 27.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.3% | 17.4% | 13.9% | 21.3% | 30.2% | 30.3% | 19.5% | 32.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 150,158 | 153,701 | 122,654 | 137,426 | 150,518 | 132,327 | 119,138 | 137,776 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
DANMEDA - Social security debts
The company had no debts to Sodra
DANMEDA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-08 | 2025-05-08 | 415.61 |
| 2025-05-07 | 2025-05-07 | 410.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
DANMEDA, UAB (company code 124266074) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, revenue increased to €551.1K, up 15.6% year on year from €476.6K in 2024 and 4.1% above 2023. Net profit improved to €150.7K in 2025 from €80.7K in 2024 and €136.0K in 2023, while the profit margin strengthened to 27.4% after 16.9% in 2024 and 25.7% in 2023. The balance sheet also expanded: total assets reached €1.13M at year-end 2025, supported by equity of €1.11M and liabilities of €25.4K. Equity accounted for 97.8% of assets, and debt to equity remained very low at 0.02. Return on equity was 13.6% and return on assets 13.3%. Asset turnover stood at 0.49x. Revenue per employee was €137.8K and profit per employee was €37.7K, indicating solid operating efficiency.